Number (%) of patients in the AIM trial in RAPID3 response categories as compared to EULAR-DAS28 response categories.
| AIM Trial Treatment Groups | EULAR-DAS28 Response Categories | EULAR-DAS28 No. (%) Patients | RAPID3 Response Categories, No. (%) Patients | ||
|---|---|---|---|---|---|
| Good (improve > 3.6 units) | Moderate (> 1.8 and ≤ 3.6 units) | Poor (improve ≤ 1.8 units) | |||
| Abatacept (kappa 0.35, weighted kappa 0.40) | Good | 102 (27) | 67 (66) | 29 (28) | 6 (6) |
| Moderate | 233 (62) | 63 (27) | 130 (56) | 40 (17) | |
| Poor | 39 (10) | 2 (5) | 8 (21) | 29 (74) | |
| Total | 374 (100) | 132 (35) | 167 (45) | 75 (20) | |
| Control (kappa 0.29, weighted kappa 0.36) | Good | 7 (4) | 5 (71) | 2 (29) | 0 |
| Moderate | 108 (59) | 22 (20) | 56 (52) | 30 (28) | |
| Poor | 68 (37) | 2 (3) | 20 (29) | 46 (68) | |
| Total | 183 (100) | 29 (16) | 78 (43) | 76 (42) | |
| All patients (kappa 0.35, weighted kappa 0.43) | Good | 109 (20) | 72 (66) | 31 (28) | 6 (6) |
| Moderate | 341 (61) | 85 (25) | 186 (55) | 70 (21) | |
| Poor | 107 (19) | 4 (4) | 28 (11) | 75 (70) | |
| Total | 557 (100) | 161 (29) | 245 (44) | 151 (27) | |
AIM: Abatacept in Inadequate Response to Methotrexate; RAPID3: Routine Assessment of Patient Index Data; EULAR: European League Against Rheumatism; DAS28: 28-joint Disease Activity Score.